Clinical trials
Phase 1/2 Triple Negative Breast Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
105 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 9 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 8 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 31 |
| Completed | 29 |
| Terminated | 28 |
| Active, not recruiting | 14 |
| Not yet recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 4 |
| Genmab | 4 |
| Gilead Sciences | 3 |
| Incyte Biosciences International Sàrl | 3 |
| Vanderbilt-Ingram Cancer Center | 3 |
| AstraZeneca | 2 |
| BicycleTx Limited | 2 |
| Eisai Inc. | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| Kari Wisinski | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 105 |
| Carcinoma, Non-Small-Cell Lung | 41 |
| Breast Neoplasms | 34 |
| Squamous Cell Carcinoma of Head and Neck | 28 |
| Ovarian Neoplasms | 27 |
| Melanoma | 22 |
| Endometrial Neoplasms | 19 |
| Colorectal Neoplasms | 18 |
| Neoplasm Metastasis | 18 |
| Carcinoma, Renal Cell | 17 |
Trials
Showing 1 to 25 of 105. Each trial links to its page on Pharma Observatory.
5 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.